A new vaccine called Capvaxive has been approved by the US FDA to prevent invasive pneumococcal disease and pneumonia in adults. The vaccine protects against 21 serotypes responsible for 84% of invasive pneumococcal disease cases in adults aged 50 or older. The CDC advisory panel will meet in June to discuss the vaccine’s approval. Testing showed the vaccine was well tolerated, with common side effects being pain at the injection site, fatigue, headaches, and muscle aches. Capvaxive can prevent pneumonia caused by serotypes not covered by other vaccines. The wholesale price is $287 per dose, but access may be available at no cost with CDC recommendation.
Source link
New Pneumococcal Vaccine Approved
